403 Error
Sorry, the page you have requested
may have been moved or deleted.
Sorry, the page you have requested
may have been moved or deleted.
VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:
Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.
It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.
VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.
NTRK, neurotrophic receptor tyrosine kinase; TRK, tropomyosin receptor kinase.
VITRAKVI may cause serious side effects, including:
Your healthcare provider may decrease your dose, temporarily stop or permanently stop your treatment with VITRAKVI if you develop serious side effects.
Before taking VITRAKVI, tell your healthcare provider about all of your medical conditions, including if you:
While on VITRAKVI, you should avoid:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter (OTC) medicines, vitamins, and herbal supplements. Certain other medicines may affect how VITRAKVI works and VITRAKVI may affect how other medicines work.
The most common side effects with VITRAKVI include:
VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects with VITRAKVI. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:
Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.
It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.
VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.
NTRK, neurotrophic receptor tyrosine kinase; TRK, tropomyosin receptor kinase.
For important risk and use information about VITRAKVI, please see the full Prescribing Information.
For Bayer products, you can report these directly to Bayer by clicking here.
© 2023 Bayer. Bayer, the Bayer Cross, and VITRAKVI are registered trademarks of Bayer, and TRAK Assist and VITRAKVI Commitment Program are trademarks of Bayer. All other trademarks are the property of their respective owners.
This site is intended for US audiences only.
Last updated on 09/2023